ENTRY       D12180                      Drug
NAME        Talquetamab (USAN/INN);
            Talquetamab-tgvs;
            Talvey (TN)
PRODUCT     TALVEY (Janssen Biotech)
FORMULA     C6410H9938N1716O2006S45
EXACT_MASS  144489.5821
MOL_WEIGHT  144578.7133
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL INPYNSDTNY
            AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARVA LRVALDYWGQ GTLVTVSSAS
            TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EAAGGPSVFL
            FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
            VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ
            VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV
            FSCSVMHEAL HNHYTQKSLS LSLGK
            (heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR IRSKYNNYAT
            YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR HGNFGNSYVS WFAYWGQGTL
            VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ
            FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT SKAKGQPRE PQVYTLPPSQ
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFL LYSKLTVDKS
            RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS ASYRYSGVPS
            RFSGSGSGTE FTLTISNLQP EDFATYYCQQ YNRYPYTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (light chain)
            QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI GGTNKRAPGT
            PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF GGGTKLTVLG QPKAAPSVTL
            FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
            LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
            (Disulfide bridge: H22-H96, H132-L214, H145-H201, H224-h231, H227-h234, H259-H319, H365-H423, h22-h98, h139-l214, h152-h208, h266-h326, h372-h430, L23-L88, L134-L194, l22-l90, l137-l196)
  TYPE      Peptide
REMARK      Product: D12180<US>
EFFICACY    Antineoplastic
  DISEASE   Multiple myeloma [DS:H00010]
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of multiple myeloma
TARGET      GPRC5D [HSA:55507] [KO:K04621]
            CD3E [HSA:916] [KO:K06451]
  PATHWAY   hsa04640(916)  Hematopoietic cell lineage
            hsa04660(916)  T cell receptor signaling pathway
BRITE       Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Metabotropic glutamate receptor family
               Orphan GPRC5
                GPRC5D
                 D12180  Talquetamab (USAN/INN) &lt;US&gt;
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D12180  Talquetamab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12180
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12180
DBLINKS     CAS: 2226212-40-2
///
